Skip to content

US · RVMDW · BIOTECHNOLOGY

Revolution Medicines, Inc. Warrant (RVMDW) intrinsic value and stock valuation

$6.40as of 2026-11-21 · Mkt cap 41.8B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Revolution Medicines, Inc. Warrant DCF and intrinsic value

InvestorsCraft values RVMDW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RVMDW’s statements →

Revolution Medicines, Inc. Warrant Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Redwood City, CA 94063 revmed.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-1.13B
20172025
Free cash flow
-$-913.73M
20172025
Total equity
$1.63B+28% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$11.6M$35.4M$29.4M
Operating income-$-1.18B-$-689.52M-$-487.19M-$-258.28M-$-188.01M
Net income-$-1.13B-$-600.09M-$-436.37M-$-248.71M-$-187.09M
EPSd-$-5.95M-$-3.58M-$-3.86M-$-3.08M-$-2.57M
Operating cash flow-$-897.74M-$-557.44M-$-350.57M-$-224.4M-$-147.18M
Capital expenditure-$-15.99M-$-10.31M-$-7.73M-$-10.82M-$-6.53M
Free cash flow-$-913.73M-$-567.74M-$-358.3M-$-235.22M-$-153.71M
Total assets$2.35B$2.56B$2.06B$811.9M$738M
Total debt$158.7M$135.8M$87.9M$64.2M$66.6M
Net debt-$-225.04M-$-407.22M-$-608.2M-$-97.21M-$-41.86M
Total equity$1.63B$2.27B$1.83B$685.2M$602.6M
Cash and short-term investments$2.03B$2.29B$1.85B$644.9M$577.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$11.6M$35.4M$29.4M
Cost of revenue$16.6M$0.00$0.00$0.00$0.00
Gross profit-$-16.56M$0.00$11.6M$35.4M$29.4M
Research and development expenses$978.7M$592.2M$423.1M$253.1M$187M
Selling, general and administrative expenses$187.1M$97.3M$75.6M$40.6M$30.5M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$1.17B$689.5M$498.8M$293.7M$217.4M
Cost and expenses$1.18B$689.5M$498.8M$293.7M$217.4M
Interest income$90.7M$86.9M$47.5M$9.15M$930K
Interest expense$24.2M$0.00$300K$0.00$10K
Depreciation and amortization$16.6M$11.8M$9.31M$9.66M$7.33M
Ebitda-$-1.09B-$-589.02M-$-430.28M-$-239.47M-$-179.75M
Operating income-$-1.18B-$-689.52M-$-487.19M-$-258.28M-$-188.01M
Total other income/expenses, net$51.1M$88.7M$47.3M$9.15M$920K
Income before tax-$-1.13B-$-600.85M-$-439.89M-$-249.12M-$-187.09M
Income tax expense$0.00-$-750K-$-3.52M-$-420K$0.00
Net income-$-1.13B-$-600.09M-$-436.37M-$-248.71M-$-187.09M
Weighted average shares outstanding$190.1M$167.7M$113.2M$80.6M$72.8M
Weighted average diluted shares outstanding$190.1M$167.7M$113.2M$80.6M$72.8M
Balance sheet
20252024202320222021
Cash and short-term investments$2.03B$2.29B$1.85B$644.9M$577.1M
Net receivables$0.00$0.00$1.25M$4.67M$5.93M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$2.08B$2.33B$1.88B$660.2M$589.8M
Property, plant and equipment, net$165.3M$141.8M$100M$73.7M$71.2M
Goodwill and intangible assets$70.4M$71.3M$72.4M$73.4M$74.5M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$279.5M$230.7M$182.4M$151.8M$148.2M
Total assets$2.35B$2.56B$2.06B$811.9M$738M
Accounts payable$64.6M$54.4M$61.8M$21.3M$14.1M
Short-term debt$16.5M$12.9M$7.37M$6.77M$6.21M
Deferred revenue$0.00$0.00$0.00$4.46M$12.4M
Total current liabilities$290.4M$163.9M$143.9M$62M$60.4M
Long-term debt$142.2M$123M$80.6M$57.4M$60.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$6.57M
Total non-current liabilities$432.8M$129.2M$91.7M$64.8M$75.1M
Capital lease obligations$16.5M$135.8M$87.9M$64.2M$66.6M
Total liabilities$723.2M$293.1M$235.5M$126.7M$135.4M
Common stock$20K$20K$20K$10K$10K
Retained earnings-$-2.87B-$-1.74B-$-1.14B-$-701.34M-$-452.64M
Accumulated other comprehensive income (loss)$3.24M$1.32M$540K-$-1.78M-$-380K
Total equity$1.63B$2.27B$1.83B$685.2M$602.6M
Total investments$1.64B$1.75B$1.16B$483.5M$468.6M
Total debt$158.7M$135.8M$87.9M$64.2M$66.6M
Net debt-$-225.04M-$-407.22M-$-608.2M-$-97.21M-$-41.86M
Cash flow statement
20252024202320222021
Net income-$-1.13B-$-600.09M-$-436.37M-$-248.71M-$-187.09M
Depreciation and amortization-$-26.96M$11.8M$9.31M$9.66M$7.33M
Stock-based compensation$118.4M$79.2M$61.8M$31.2M$20.7M
Change in working capital$86.8M$1.17M$40.7M-$-13.49M$8.72M
Accounts receivable$0.00$1.25M$3.42M$1.26M$460K
Inventory$0.00$0.00$0.00$0.00$7.68M
Accounts payable$9.54M-$-6.46M$32.5M$7.29M$2.24M
Net cash provided by operating activities-$-897.74M-$-557.44M-$-350.57M-$-224.4M-$-147.18M
Investments in property, plant and equipment-$-15.99M-$-10.31M-$-7.73M-$-10.82M-$-6.53M
Acquisitions, net$0.00$0.00$0.00$13.3M$135.6M
Net cash used for investing activities$118.1M-$-554.39M-$-342.6M-$-24.12M-$-142.12M
Common stock issued$377.1M$959.1M$392.4M$298.1M$291.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$621.5M$959.4M$1.23B$301.4M$294.2M
Net change in cash-$-158.16M-$-153.08M$534.7M$52.9M$4.88M
Cash at end of period$388.6M$543.1M$696.2M$163.2M$110.2M
Operating cash flow-$-897.74M-$-557.44M-$-350.57M-$-224.4M-$-147.18M
Capital expenditure-$-15.99M-$-10.31M-$-7.73M-$-10.82M-$-6.53M
Free cash flow-$-913.73M-$-567.74M-$-358.3M-$-235.22M-$-153.71M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Revolution Medicines, Inc. Warrant

        Revolution Medicines, Inc. is a biopharmaceutical company in the clinical development phase, concentrating on creating innovative, precisely targeted therapies for cancers driven by RAS pathway dysregulation. The firm's drug development portfolio features both RAS(ON) inhibitors, which are designed for potential use as single agents, in conjunction with other RAS(ON) inhibitors, or alongside RAS companion inhibitors and various therapeutic compounds. Additionally, its pipeline includes dedicated RAS companion inhibitors intended for synergistic treatment approaches. Among its RAS(ON) inhibitors currently in Phase 1 clinical trials are RMC-6236 (targeting a broad spectrum of RAS mutations), RMC-6291 (specific to G12C), and RMC-9805 (for G12D). Further compounds in preclinical or early development include RMC-5127 (for G12V), RMC-0708 (for Q61H), and RMC-8839 (for G13C), along with ongoing programs focused on G12R and other distinct molecular targets. In the realm of RAS companion inhibitors, RMC-4630 is advancing through Phase 2 clinical assessment, while RMC-5552 is undergoing Phase 1 evaluation. Revolution Medicines, Inc. was founded in 2014 and operates from its headquarters in Redwood City, California.

        CEO
        Mark A. Goldsmith
        Employees
        883
        Beta
        1.40

        Explore

        Frequently asked questions

        What is the intrinsic value of Revolution Medicines, Inc. Warrant (RVMDW)?

        InvestorsCraft does not currently publish an intrinsic value for RVMDW. How the IC value is calculated.

        Is RVMDW undervalued?

        InvestorsCraft does not publish an undervaluation signal for RVMDW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.